Chesterbrook’s Persevere Therapeutics marked its emergence from stealth mode with a completed equity financing and product acquisition.
Chesterbrook-based Persevere Therapeutics marked its emergence from stealth mode last week with completed equity financing and product acquisition, writes John George for the Philadelphia Business Journal.
Focused on developing cancer treatments, the biotechnology startup raised $1.57 million in a seed financing round. A Securities and Exchange Commission filing shows that the company is looking to raise $5 million overall…